share_log

PharmaCielo Q2 Revenue Soars 375% YoY, Raises Additional $4.6M In Oversubscribed Debenture Financing

PharmaCielo Q2 Revenue Soars 375% YoY, Raises Additional $4.6M In Oversubscribed Debenture Financing

PharmaCielo第二季度营收同比飙升375%,额外筹集460万美元超额认购债券融资
Benzinga Real-time News ·  2022/08/31 08:38
PharmaCielo Ltd. (OTCQX:PCLOF) (TSXV:PCLO) Q2 2022 revenue was CA$2.1 million, a 375% increase compared to CA$446,000 in Q2 2021.
PharmaCielo Ltd.(场外交易:PCLOF)(多伦多证券交易所股票代码:PCLO)2022年第二季度收入为210万加元,增长375%相比之下,2021年第二季度为446,000加元。
Q2 2022 Financial Highlights
2022年第二季度财务亮点
Net loss was CA$3.5 million compared to net loss of CA$7.2 million in Q2 2021. Adjusted EBITDA was a loss of CA$2.1 million compared to a loss of CA$4.5 million in Q2 2021. Cash equivalents of CA$1 million at June 30, 2022, compared to CA$5.3 million at December 31, 2021. Gross profit was CA$834,814 compared to a loss of CA$807,700 in Q2 2021.
净亏损为350万加元相比之下,2021年第二季度净亏损为720万加元。 调整后的EBITDA亏损210万加元相比之下,2021年第二季度亏损450万加元。 C100万加元的灰当量截至2022年6月30日,与2021年12月31日的530万加元相比。 毛利润为加元834,814相比之下,2021年第二季度亏损807,700加元。
Bill Petron, chairman and CEO of PharmaCielo stated, "The team has made substantial progress in the first six months of the year. We continue to build the revenue line...
比尔·彼得龙,PharmaCielo董事长兼首席执行官表示...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发